Comparative Pharmacology
Head-to-head clinical analysis: BREVICON 21 DAY versus CYCLAFEM 0 5 35.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREVICON 21 DAY versus CYCLAFEM 0 5 35.
BREVICON 21-DAY vs CYCLAFEM 0.5/35
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH, LH) release via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation. Increases viscosity of cervical mucus and alters endometrial lining to impede sperm penetration and implantation.
Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Inhibits gonadotropin release, suppressing ovulation. Increases cervical mucus viscosity and alters endometrium, reducing sperm penetration and implantation.
One tablet (0.5 mg norethindrone and 0.035 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days off.
One tablet (0.5 mg norethindrone/35 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days (or no tablets) per cycle.
None Documented
None Documented
Norethindrone: 7-8 hours; Ethinyl estradiol: 13-17 hours. Clinical context: Steady state reached within 5-7 days; missed pills may reduce contraceptive efficacy.
Terminal elimination half-life of norethindrone is 5-14 hours (mean 7.6 hours); ethinyl estradiol half-life is 7-20 hours (mean ~13 hours). Steady-state is achieved within 5-7 days.
Urine (50-60% as metabolites, <10% unchanged); feces (30-40% as metabolites); biliary (minor).
Renal excretion accounts for approximately 50-60% of the dose (as metabolites), with 30-40% excreted in feces via biliary elimination. Unchanged drug is minimal in urine.
Category C
Category C
Oral Contraceptive
Oral Contraceptive